Wender-Reimherr self-report questionnaire on adult ADHD : German version.

CONCLUSION: The WR-SB is a brief, self-report instrument and an economical alternative to assess adult ADHD symptomatology using the Utah criteria. The results of this evaluation study showed the WR-SB to be a valid and reliable measurement for both clinical and research purposes. PMID: 27206708 [PubMed - as supplied by publisher]
Source: Der Nervenarzt - Category: Neurology Authors: Tags: Nervenarzt Source Type: research

Related Links:

Publication date: Available online 15 November 2019Source: Journal of Chemical NeuroanatomyAuthor(s): Amir Raoofi, Abass Aliaghaei, Mohammad-Amin Abdollahifar, Mahdi Eskandarian Boroujeni, Sara Sadat javadinia, Hadi Atabati, Beheshteh AbouhamzehAbstractBackground and AimStated in previous studies, physicians are typically prescribing methylphenidate (MPH), commonly known as Ritalin, for children diagnosed with attention deficit hyperactivity disorder (ADHD). Nevertheless, researchers have not still understood mechanisms of this stimulant medication. Research has also found an association between apoptosis signaling pathway...
Source: Journal of Chemical Neuroanatomy - Category: Neuroscience Source Type: research
While recreational marijuana is legal in 11 states as of November 2019, more states gravitating toward legalizing the recreational use of the substance, and 33 states allowing medical marijuana, there’s apparently no stopping this trend. Cannabis, in the form of marijuana, hemp, and cannabidiol (CBD)  is being used for pain relief, to alleviate stress, cope with anxiety, and a number of other mental health disorders and addictions. Yet, there’s a dearth of clinical studies that have been conducted on the overall effects on a user’s health. Clearly, as Crain’s Detroit Business points out, more ...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Medications Substance Abuse Cannabis Marijuana Source Type: blogs
ADHD, or attention deficit hyperactivity disorder, is the most common neurobehavioral disorder of childhood. It affects approximately 7% to 8% of all children and youth in the US. As the American Academy of Pediatrics (AAP) pointed out in their recent clinical practice guideline for ADHD, that’s more than the mental health system can handle, which means that pediatricians need to step up and help out. So, if your child is having problems with attention, focus, hyperactivity, impulsivity, or some combination of those, and is at least 4 years old, your first step should be an appointment with your child’s primary...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Adolescent health Children's Health Neurological conditions Parenting Source Type: blogs
Translational Psychiatry, Published online: 15 November 2019; doi:10.1038/s41398-019-0619-yAdult attention-deficit/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[11C]methylreboxetine positron emission tomography study
Source: Translational Psychiatry - Category: Psychiatry Authors: Source Type: research
AbstractPurpose of ReviewAttention deficit hyperactivity disorder and methamphetamine use disorder are common comorbidities. National data regarding methamphetamine use is available per the most recent SAMSHA report. Even though attention deficit hyperactivity disorder and methamphetamine seem to commonly coexist, we do not have national figures which would provide a more comprehensive picture. The purpose of the article is to highlight this comorbidity and discuss some of the possible shared neurobiological and other pertinent overlapping features.Recent FindingsPer the 2017 SAMSHA report, among the 8.3 million younger ad...
Source: Current Developmental Disorders Reports - Category: Child Development Source Type: research
Publication date: Available online 12 November 2019Source: NeuroImageAuthor(s): Juha Salmi, Mostafa Metwaly, Jussi Tohka, Kimmo Alho, Sami Leppämäki, Pekka Tani, Anniina Koski, Tamara Vanderwal, Matti LaineAbstractIndividuals with attention-deficit/hyperactivity disorder (ADHD) have difficulties navigating dynamic everyday situations that contain multiple sensory inputs that need to either be attended to or ignored. As conventional experimental tasks lack this type of everyday complexity, we administered a film-based multi-talker condition with auditory distractors in the background. ADHD-related aberrant brain r...
Source: NeuroImage - Category: Neuroscience Source Type: research
CONCLUSION: This case report suggests that health and wellness coaching can be effective in supporting beneficial outcomes and can be useful in the multimodal management of ADHD. PMID: 31710834 [PubMed - in process]
Source: The Permanente journal - Category: General Medicine Tags: Perm J Source Type: research
The fate of a local company ’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. If granted, that could mean gettin g the treatment to patients in the second half of 2020. Supernus has put the product candidate through a handful of phase 3 clinical trials, to study its ability to reduce ADHD…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Up to 60% of children with Attention-Deficit/Hyperactivity Disorder (ADHD) meet diagnostic criteria for at least one anxiety disorder, including Social, Generalized and/or Separation Disorder. Anxiety in child...
Source: BMC Psychiatry - Category: Psychiatry Authors: Tags: Study protocol Source Type: research
The fate of a local company ’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. If granted, that could mean gettin g the treatment to patients in the second half of 2020. Supernus has put the product candidate through a handful of phase 3 clinical trials, to study its ability to reduce ADHD…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
More News: ADHD | Hyperactivity | Neurology | Study